Abstract：
Macular degeneration (MD) is a group of diseases characterized by irreversible and progressive vision loss. Patients with MD suffer from severely impaired central vision, especially elderly people. Currently, only one type of MD, wet age-related macular degeneration (AMD), can be treated with anti-vascular endothelium growth factor (VEGF) drugs. Other types of MD remain difficult to treat. With the advent of human pluripotent stem cells (hPSCs) and their differentiation into retinal pigmented epithelium (RPE), it is promising to treat patients with MD by transplantation of hPSC-derived RPE into the subretinal space. In this review, the current progress in hPSC-derived RPE transplantation for the treatment of patients with MD is described from bench to bedside, including hPSC differentiation into RPE and the characterization and usage of hPSC-derived RPE for transplantation into patients with MD.
摘要：
黄斑变性（MD）是一组以不可逆和进行性视力丧失为特征的疾病。患有MD的患者患有严重的中央视力受损，尤其是老年人。目前,只有一种类型的MD，湿性年龄相关性黄斑变性（AMD），可以用抗血管内皮生长因子（VEGF）药物治疗。其他类型的MD仍然难以治疗。随着人类多能干细胞（hPSC）的出现及其向视网膜色素上皮（RPE）的分化，通过将hPSC衍生的RPE移植到视网膜下间隙来治疗MD患者是有希望的。在这次审查中,从工作台到床边描述了hPSC衍生的RPE移植治疗MD患者的当前进展，包括hPSC分化为RPE，以及hPSC衍生的RPE移植到MD患者的特征和用途。
